Medtronic (MDT) reported $8.93 billion in revenue for the quarter ended April 2025, representing a year-over-year increase of 3.9%. EPS of $1.62 for the same period compares to $1.46 a year ago.
The reported revenue represents a surprise of +1.08% over the Zacks Consensus Estimate of $8.83 billion. With the consensus EPS estimate being $1.58, the EPS surprise was +2.53%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Medtronic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- U.S. Revenue: $4.55 billion compared to the $4.50 billion average estimate based on three analysts. The reported number represents a change of +4.7% year over year.
- Net Sales- U.S. Revenue- Neuroscience- Specialty Therapies: $431 million versus $448.55 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.8% change.
- Net sales- U.S.- Other: $17 million versus $8.56 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -34.6% change.
- Net Sales- ROW- Cardiovascular- Cardiac Rhythm & Heart Failure: $858 million versus the two-analyst average estimate of $816.74 million.
- Net Sales- World Wide Revenue- Diabetes: $728 million compared to the $704.13 million average estimate based on six analysts. The reported number represents a change of +10.3% year over year.
- Net Sales- World Wide Revenue- Neuroscience: $2.62 billion versus the six-analyst average estimate of $2.55 billion. The reported number represents a year-over-year change of +3%.
- Net Sales- World Wide Revenue- Cardiovascular: $3.34 billion versus the six-analyst average estimate of $3.28 billion. The reported number represents a year-over-year change of +6.6%.
- Net Sales- World Wide Revenue- Medical Surgical: $2.21 billion compared to the $2.28 billion average estimate based on six analysts. The reported number represents a change of +0.6% year over year.
- Net sales- Other: $31 million versus $27.80 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -45.6% change.
- Net Sales- World Wide Revenue- Cardiovascular- Cardiac Rhythm & Heart Failure: $1.73 billion versus $1.68 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
- Net Sales- World Wide Revenue- Cardiovascular- Structural Heart & Aortic: $944 million compared to the $933.21 million average estimate based on five analysts. The reported number represents a change of +6.9% year over year.
- Net Sales- World Wide Revenue- Medical Surgical- Surgical & Endoscopy: $1.71 billion versus $1.72 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +0.2% change.
View all Key Company Metrics for Medtronic here>>>
Shares of Medtronic have returned +3.6% over the past month versus the Zacks S&P 500 composite's +12.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Medtronic PLC (MDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
